MELBOURNE, Australia and SAN
FRANCISCO, Jan. 3, 2023 /PRNewswire/ -- Alterity
Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the
Company"), a biotechnology company dedicated to developing disease
modifying treatments for neurodegenerative diseases, today
announced that David Stamler, M.D.,
Chief Executive Officer will participate in the Sachs Associates
6th Annual Neuroscience Innovation Forum (NIF). The
forum is taking place Sunday, January 8,
2022, as part of the activities surrounding the annual J.P.
Morgan Healthcare Conference.
At the conference, Dr. Stamler will be featured on a panel
entitled, "New Approaches to Parkinson's and Movement Disorders."
He will also present a company update and participate in investor
and business development meetings.
The program for the 6th Annual NIF is designed to
cover the latest developments in global bio-partnering and
investment, with additional panels covering scientific advances in
key therapeutic areas of neurodegenerative diseases and CNS more
broadly, which includes neuropsychiatry, ophthalmology, neurotech
and digital therapeutics.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company
dedicated to creating an alternate future for people
living with neurodegenerative diseases. The Company's lead
asset, ATH434, has the potential to treat various Parkinsonian
disorders. Alterity also has a broad drug discovery platform
generating patentable chemical compounds to intercede in disease
processes. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further
information please visit the Company's web site at
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics
View original content to download
SOURCE Alterity Therapeutics Limited